Artis Ventures — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.
BiotechDeep TechMedical DevicesSeattle, US
Marc Lajoie(Co-founder & Chief Executive Officer)Scott Boyken(Co-founder & Chief Technology Officer)Stanley Riddell(Co-Founder and Scientific Advisor)Aaron Foster(Executive Officer)Charity Scripture(Executive Officer)Eric Soller(Executive Officer)
Co-investorsRA CapitalAbstract VenturesAtinum Investment Co. Ltd.Civilization Ventures Management, LlcModi VenturesPlayground Global+1 more
Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity.
BiotechDeep TechBerkeley, US
Joshua Yang(Founder & CEO)Daniel Estandian(Founder)Ed Boyden(Founder)Josh Yang(Founder)in
BoardCraig Asher(Director)inJimmy Yun(Director)
Co-investorsBlack FlagCivilization Ventures Management, LlcFoundersX VenturesLongeVCModi VenturesOMX Ventures+3 more
Siren Biotechnology develops next-generation AAV (adeno-associated virus) platforms for gene therapy applications, including gene repair, gene transfer, and gene editing.
BiotechDigital HealthMedical DevicesSan Francisco, US
Dr. Nicole Paulk(CEO, Founder, and President)Nicole Paulk(Executive Officer, Director)Lauren Kelly(Founder)inSharon Tetlow(Director)Brad Allen(Director)
Co-investorsAvilaCarnrite VenturesCivilization Ventures Management, LlcHAWKTAILNZVCPlum Alley Investments+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.